Development and characterization of novel erythropoiesis stimulating protein (NESP).
about
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in EuropeThe glycan role in the glycopeptide immunogenicity revealed by atomistic simulations and spectroscopic experiments on the multiple sclerosis biomarker CSF114(Glc)Characterization of N- and O-glycopeptides of recombinant human erythropoietins as potential biomarkers for doping analysis by means of microscale sample purification combined with MALDI-TOF and quadrupole IT/RTOF mass spectrometry.Procedures for monitoring recombinant erythropoietin and analogues in doping control.CIEF and MALDI-TOF-MS methods for analyzing forms of the glycoprotein VEGF 165.The role of anemia management in improving outcomes for African-Americans with chronic kidney diseaseA new insect cell glycoengineering approach provides baculovirus-inducible glycogene expression and increases human-type glycosylation efficiency.Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin.Neuroprotective activity of a new erythropoietin formulation with increased penetration in the central nervous systemGeneration of biologically active multi-sialylated recombinant human EPOFc in plants.Glycosylation-modified erythropoietin with improved half-life and biological activity.A biomathematical model of human erythropoiesis under erythropoietin and chemotherapy administration.Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease.Glycosylation characterization of recombinant human erythropoietin produced in glycoengineered Pichia pastoris by mass spectrometry.The efficacy of rHuEPO in cancer-related anaemia.The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee.The effects of potential neuroprotective agents on rat facial function recovery following facial nerve injury.Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysisEvolving treatment approaches for early breast cancer.Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.Antioxidant and antiapoptotic effects of darbepoetin-α against traumatic brain injury in rats.Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study.Toward Homogeneous Erythropoietin: Application of Metal Free Dethiylation in the Chemical Synthesis of the Ala79-Arg166 Glycopeptide Domain.Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents.Strategies to extend plasma half-lives of recombinant antibodies.Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists.Unit dosing of darbepoetin alfa for thetreatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: Results of a phase IIIb, 27-week, multicenter, open-label study in Greek patientsDelivery of therapeutic proteins.Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact.Erythropoiesis-stimulating agents and heart failure.Hematide™ for the treatment of chronic kidney disease-related anemia.Recent developments in doping testing for erythropoietin.Current state and perspectives on erythropoietin production.Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin.Advances and challenges in developing cytokine fusion proteins as improved therapeutics.Erythropoiesis stimulating agents: approaches to modulate activity.Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.An overview of recent developments in the treatment of heart failure: update from the ESC Congress 2013.
P2860
Q26865984-A0F7AAFC-E9CE-4BF5-8CB7-93CF618730FDQ30628296-3CEF9B4A-A835-4974-B1E8-1B1EC85652AAQ33225173-7C30E93F-7D03-473A-BD7C-F6ABC2C12519Q33285252-7C6BFC89-A245-427B-87D5-C5EA56B17383Q33431332-CA42E3F1-1674-49E2-BF38-3BDF589F5771Q33646679-429053E8-3DD0-4B08-B244-F3CF88C69AAFQ33893766-F30AE6F3-DE2E-4443-9F73-516F39AE53F1Q34034670-5CDA3677-8EED-4A16-AC5E-A43B2B1C933EQ34176933-C31B8064-5B4B-4BD8-9D2C-9EFD4F2F2596Q34571378-4EB82F61-925A-4DCE-B98C-DAFE419A8586Q34616456-3BE586DB-C4EF-43B1-9EE7-54DFA46FE31BQ34766672-F82309F4-E770-4212-BFA9-CEAC269B1125Q34834837-614CDA5E-C482-491E-B90F-A2B3A6E0CE5CQ35066979-159FB813-C505-4E10-8616-BF1664086233Q35096645-63B1D9E7-856C-4FAC-91E0-D35E00450E34Q35128983-E6A77A07-4D06-4C4D-926E-28B70713846BQ35556725-3F3DA0BA-BC09-4B3B-882F-09AE5C9AEBA8Q35797921-A23635F8-3FEE-4E4A-B6DC-7712B21A6952Q35798280-1E677CE8-2C85-4748-8606-1AD2B400E6CEQ36072087-5E528FA5-B2CC-4522-84C9-E673DFFF90AFQ36146443-B09D28D1-93BC-4B25-8C25-C03D2C4AC014Q36220699-306CD2F1-B3C5-4167-96B4-8B07119D76FFQ36655932-815F31B4-C328-45B0-A747-AD64735E9FDAQ36754652-A6D93955-9B98-4217-BBEE-40D72F0A852EQ37308372-D750243A-BDD9-4618-A6F9-C5E6D40C0907Q37505008-83CEAD06-909F-4C57-B895-E493E426B6BAQ37614087-78DF9DEA-7F2D-4188-9646-209EEEA7665EQ37661090-CEDF0FD1-2464-426F-86EE-92E42208FC35Q37668486-27FBD38B-1E93-458F-B08A-288442F60EC3Q37686245-37A0A876-695C-462D-97FC-4DF6675A4821Q37802925-2FEE432F-1228-431C-BA5E-CD5A6AB0CECBQ37810076-C0E539E3-7EF5-4584-ADB3-3C87B9188DA1Q37884431-3D3434B6-7CDE-4BA2-B6D4-E67554D9247AQ38028315-FFBBB435-F70A-41D6-B271-DD79A364CDA6Q38083095-C4D82A4D-3C1A-4CA9-8BF7-182EB0FC8FF2Q38088357-8C5D8968-92B2-49CB-82B7-8B88BD7F51A9Q38121067-0FF40C5E-4EBF-4ED7-B625-7C13E9888282Q38126361-2A2933EA-1100-4AB7-B5E6-5712269BCA18Q38134288-03A7E381-79F2-41FF-A516-ADC40DB121EBQ38184627-547C81C2-F35E-4688-B0D3-E824F0E21697
P2860
Development and characterization of novel erythropoiesis stimulating protein (NESP).
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Development and characterization of novel erythropoiesis stimulating protein (NESP).
@ast
Development and characterization of novel erythropoiesis stimulating protein (NESP).
@en
Development and characterization of novel erythropoiesis stimulating protein
@nl
type
label
Development and characterization of novel erythropoiesis stimulating protein (NESP).
@ast
Development and characterization of novel erythropoiesis stimulating protein (NESP).
@en
Development and characterization of novel erythropoiesis stimulating protein
@nl
prefLabel
Development and characterization of novel erythropoiesis stimulating protein (NESP).
@ast
Development and characterization of novel erythropoiesis stimulating protein (NESP).
@en
Development and characterization of novel erythropoiesis stimulating protein
@nl
P356
P1476
Development and characterization of novel erythropoiesis stimulating protein (NESP).
@en
P2093
P356
10.1093/NDT/16.SUPPL_3.3
P407
P478
16 Suppl 3
P577
2001-01-01T00:00:00Z